Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B

information fournie par Boursorama •17/10/2017 à 17:45

Data Featured in a Poster Presentation at AASLD Liver Meeting 2017

Strasbourg (France), October 17, 2017- 5:45 pm CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, will be presenting a poster on TG1050 first promising clinical results at the American Association for the Study of Liver Diseases (AASLD) Meeting 2017, in Washington, DC, October 20-24.

TG1050 is a therapeutic vaccine, that is currently being evaluated in an international first-in-man Phase 1/1b trial in patients with chronic hepatitis B (or chronic HBV infection) receiving nucleoside analog-based standard of care. The recruitment of the trial has been completed and the patients’ follow up is ongoing.

During the poster presentation, Transgene will provide details on the good safety profile of the product, and will present preliminary results indicating that TG1050 induces a robust specific cell-mediated immune response in patients that have received a single dose of TG1050.

Poster title: Phase 1b clinical trial of TG1050, a novel HBV-targeted immunotherapy, in NUC suppressed chronic hepatitis B patients: safety and early immunological data following single administration

• Poster ID: 906
• Date, time, location: Poster Session II, Saturday, 21 October 2017, 5:30–7:30 pm, Hall D

The abstract published in Hepatology can be downloaded on the AASLD website.
.../...